Literature DB >> 17049328

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.

Akira Nakamura1, Chi Ly, Mirijana Cipetić, Natalie A Sims, Jessica Vieusseux, Vicky Kartsogiannis, Stelios Bouralexis, Hasnawati Saleh, Hong Zhou, John T Price, T John Martin, Kong Wah Ng, Matthew T Gillespie, Julian M W Quinn.   

Abstract

Osteoclast inhibitory lectin (OCIL) is a type II C-type lectin and binds NK cell-associated receptor Nkrp1d and sulfated glycosaminoglycans. OCIL is expressed by several cell types found in bone and inhibits osteoclast differentiation. To determine whether OCIL may have wider effects on bone metabolism, we examined the effects of recombinant soluble OCIL on cultured osteoblasts and pre-osteoblastic KUSA O cells. Although OCIL did not affect osteoblast proliferation or apoptosis, or the formation of alkaline phosphatase positive colonies in cultured bone marrow, OCIL profoundly inhibited mineralization by primary osteoblasts and KUSA O cells in vitro. Analysis of ascorbate-treated KUSA O cells showed that addition of OCIL reduced bone sialoprotein (BSP), osterix and osteocalcin mRNA expression, as well as alkaline phosphatase activity while, in contrast, expression of markers associated with the earlier stages of osteoblast maturation or the transcription factors Runx2, ATF4 and c-fos were not affected by OCIL treatment. Indeed, osteocalcin expression was strongly inhibited within 3 days in a dose-dependent manner, although after subsequent removal of OCIL, osteocalcin mRNA levels recovered within 4 days. OCIL treatment also reduced osteocalcin expression in BMP-2 stimulated C2C12 cells. In support of a role for OCIL in mineralization, OCIL anti-sense oligonucleotide treatment of KUSA O cells increased mineralization and osteocalcin expression. In addition, insulin-, dexamethasone- and IBMX-stimulated KUSA O cells undergo adipocyte differentiation and OCIL treatment greatly suppressed this process. Consistent with this, OCIL also reduced adiponectin and resistin mRNA expression in these cells. Our data indicate that OCIL reduces osteoblastic function in vitro and this may be due to an inhibitory effect on osteoblast maturation. In addition, the reduction of adipocyte formation in KUSA O cells by OCIL indicates that OCIL may have wider effects on the mesenchymal lineage that may be important for both bone metabolism and other connective tissue functions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17049328     DOI: 10.1016/j.bone.2006.09.001

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  13 in total

1.  EGFL6 promotes endothelial cell migration and angiogenesis through the activation of extracellular signal-regulated kinase.

Authors:  Shek Man Chim; An Qin; Jennifer Tickner; Nathan Pavlos; Tamara Davey; Hao Wang; Yajun Guo; Ming Hao Zheng; Jiake Xu
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

2.  Lectins influence chondrogenesis and osteogenesis in limb bud mesenchymal cells.

Authors:  Tahereh Talaei-Khozani; Malihezaman Monsefi; Mansoureh Ghasemi
Journal:  Glycoconj J       Date:  2011-03-01       Impact factor: 2.916

3.  Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo.

Authors:  Vicky Kartsogiannis; Natalie A Sims; Julian M W Quinn; Chi Ly; Mirijana Cipetic; Ingrid J Poulton; Emma C Walker; Hasnawati Saleh; Narelle E McGregor; Morgan E Wallace; Mark J Smyth; T John Martin; Hong Zhou; Kong Wah Ng; Matthew T Gillespie
Journal:  J Biol Chem       Date:  2008-09-08       Impact factor: 5.157

4.  Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling.

Authors:  Chang Hyun Byon; Amjad Javed; Qun Dai; John C Kappes; Thomas L Clemens; Victor M Darley-Usmar; Jay M McDonald; Yabing Chen
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

5.  TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways.

Authors:  Muzaffer Cicek; Anne Vrabel; Catherine Sturchio; Larry Pederson; John R Hawse; Malayannan Subramaniam; Thomas C Spelsberg; Merry Jo Oursler
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

Review 6.  Inhibitory C-type lectin receptors in myeloid cells.

Authors:  Pierre Redelinghuys; Gordon D Brown
Journal:  Immunol Lett       Date:  2010-10-08       Impact factor: 3.685

Review 7.  The biological function of type I receptors of bone morphogenetic protein in bone.

Authors:  Shuxian Lin; Kathy K H Svoboda; Jian Q Feng; Xinquan Jiang
Journal:  Bone Res       Date:  2016-04-05       Impact factor: 13.567

Review 8.  Role of Osteogenic Growth Peptide (OGP) and OGP(10-14) in Bone Regeneration: A Review.

Authors:  Suzane C Pigossi; Marcell C Medeiros; Sybele Saska; Joni A Cirelli; Raquel M Scarel-Caminaga
Journal:  Int J Mol Sci       Date:  2016-11-22       Impact factor: 5.923

9.  TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation.

Authors:  David J Mahoney; Katalin Mikecz; Tariq Ali; Guillaume Mabilleau; Dafna Benayahu; Anna Plaas; Caroline M Milner; Anthony J Day; Afsaneh Sabokbar
Journal:  J Biol Chem       Date:  2008-06-26       Impact factor: 5.157

10.  LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation.

Authors:  Alba Llibre; Constantino López-Macías; Teresa Marafioti; Hema Mehta; Amy Partridge; Carina Kanzig; Felice Rivellese; Jacob D Galson; Lucy J Walker; Paul Milne; Rodney E Phillips; Dominic F Kelly; Gordon J Freeman; Mohey Eldin El Shikh; Paul Klenerman; Christian B Willberg
Journal:  J Immunol       Date:  2016-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.